Bangalore (Reuters) - Takeda Pharmaceutical Co (4502.T) is to reach an agreement with Nycomed to acquire the Swiss drug firm for about 1 trillion yen ($13 billion), the Nikkei business daily reported.
The report said an announcement may be made on Wednesday.
On Friday, Japan’s largest drugmaker had denied reports that it was in talks to buy privately-held Nycomed.
Takeda will purchase all Nycomed outstanding shares from investment funds, according to the report. By bringing the Zurich-based firm under its umbrella, Takeda aims to make a full push into emerging markets, such as Eastern Europe and the former Soviet bloc, the Nikkei report said.
Nycomed registered nearly 40 percent of its 2010 sales of 3.2 billion euros, or about 370 billion yen, from these markets, the paper reported. The Japanese firm hopes to use Nycomed’s sales channels to market its own prescription drugs in the future, the Nikkei said.
In emerging markets, Takeda initially plans to sell respiratory as well as other prescription and generic drugs developed by Nycomed, the daily reported.
Reporting by Shravya Jain in Bangalore; Editing by Prem Udayabhanu